Description: Acrux Limited, together with its subsidiaries, develops and commercializes specialty and generic topical pharmaceuticals in Australia, Switzerland, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was founded in 1998 and is based in West Melbourne, Australia.
Home Page: www.acrux.com.au
103-113, Stanley Street
West Melbourne,
VIC
3003
Australia
Phone:
61 3 8379 0100
Officers
| Name | Title |
|---|---|
| Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus | CEO, MD & Exec. Director |
| Ms. Joanna Johnson B.E., BEc, ICAA | CFO & Company Sec. |
| Ms. Felicia Colagrande B.Sc., BSc (Hons), M.B.A., MBA | Product Devel. & Technical Affairs Director |
| Mr. Charles O'Sullivan B. Pharm | Portfolio Director |
| Mr. Mark Hyman | Project & Technical Devel. Director |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.72 |
| Price-to-Sales TTM: | 9.7464 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |